The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Front-Line Treatment of Pancreatic Carcinoma with Gemcitabine (GMB) in Combination with Irinotecan (CPT-11): Preliminary Results of a Multicenter Phase II Study.
 
Yoshitaka Honma
Research Funding - AstraZeneca; Daiichi Sankyo; Merck Serono; Teijin Pharma
 
Makoto Ueno
Honoraria - AstraZeneca; Lilly; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Eisai
Research Funding - AstraZeneca; Daiichi Sankyo; Eisai; Merck Serono; MSD; NanoCarrier; Ono Pharmaceutical; Shire; Taiho Pharmaceutical; Zeria Pharmaceutical
 
Yukihide Kanemitsu
No Relationships to Disclose
 
Shinichi Ohkawa
Honoraria - Lilly; Otsuka; Sandoz; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - AstraZeneca (Inst)
 
Hideaki Kitahara
No Relationships to Disclose
 
Junki Mizusawa
Honoraria - Chugai Pharma
 
Hiroshi Katayama
No Relationships to Disclose
 
Kenichi Nakamura
Honoraria - Eisai; Merck Serono; Nihonkayaku; Taiho Pharmaceutical
 
Junji Furuse
Honoraria - Astellas Pharma; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Lilly Japan; Merck Serono; Mochida Pharmaceutical Co. Ltd.; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sawai Pharmaceutical Co; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Asahi Kasei; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; MSD; Novartis; Ono Pharmaceutical; Otsuka; Sandoz; Sanofi; Sawai Pharmaceutical Co; Shionogi; Shire; Sumitomo Dainippon; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical
Speakers' Bureau - Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Baxalta/Shire (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst); Zeria Pharmaceutical (Inst)
 
Yasuhiro Shimada
Honoraria - Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck Serono; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Lilly Japan (Inst); Merck Serono (Inst); MSD K.K (Inst); Taiho Pharmaceutical (Inst)